Overview of Emerging Theranostic Twins
| Theranostic twin | Subcellular mechanism | Treated tumor entities | Organs at risk | Key characteristics |
| 68Ga-pentixafor/177Lu-pentixather | SDF1/CXCR4 axis | Multiple myeloma | Bone marrow, kidney | Agent has been applied for treatment of multiple myeloma (76,77), with complete/partial remission in most subjects (76) |
| Agent is add-on to conventional chemotherapy and conditioning regimen before autologous or allogeneic stem cell transplantation (73) | ||||
| COLPRIT trial investigates CXCR4-directed endoradiotherapy in multiple myeloma and lymphoma at early disease stage (73) | ||||
| 123I-/131I-metomidate | 11β-hydroxylase aldosterone synthase | Adrenocortical cancer | Bone marrow, adrenal gland | Partial response was seen in 1/11 patients and stable disease in 5/11 (83) |
| The novel theranostic pair 123I-/131I-azetidinylamide may increase efficacy (84) | ||||
| The currently recruiting FAMIAN trial investigates impact of 123I-metomidate on clinical management (90) | ||||
| 177Lu-3BP-277 | Neurotensin receptor 1 | Ductal pancreatic adenocarcinoma | Kidney | Neurotensin receptor 1 is promising target with overexpression in breast cancer, pancreatic adenocarcinoma, prostate cancer and lung cancer (85) |
| Feasibility study demonstrated partial response in patients with pancreatic adenocarcinoma and extensive tumor burden (86) | ||||
| PET-guided strategies for risk stratification are needed (91) |